Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)
This study is testing a new medication called evexomostat when taken along with standard treatments for a specific type of advanced breast cancer. Researchers want to see if this combination is safe and if it can help reduce blood sugar side effects often caused by standard therapies.
This study is open to men and post-menopausal women with HR-positive, HER2-negative advanced breast cancer that has specific genetic changes in the PI3K pathway. You will also need to meet other health and medical history requirements to join.
Participants will receive a combination of drugs, including evexomostat and standard treatments chosen by their doctor. Your health team will closely monitor your safety, tumor response, and blood sugar levels throughout the study.
The study is currently recruiting patients at multiple locations in California, United States. Your care team can help you find the most convenient site for your visits.
- 1Tests a new drug combination for advanced breast cancer
- 2Aims to manage and reduce blood sugar side effects
- 3Currently recruiting patients in California
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.